Skip to main content
SpringerLink
Log in

The faster the better?

  • Internal Medicine
  • Commentary
  • Published:
Internal and Emergency Medicine Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Benetti GP, Borzio M, Ramella G, et al., and GEL (Gruppo E patologico Lombardo). Daily dose of interferon alpha-2b and ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection: a randomised controlled study.Intern Emerg Med 2006, 1: 113–8.

    Article  PubMed  Google Scholar 

  2. Zeuzem S, Schmidt JM, Lee JH, Ruster B, Roth WK. Effect of interferon alfa on the dynamics of hepatitis C virus turnover in vivo.Hepatology 1996; 23: 366–71.

    PubMed  CAS  Google Scholar 

  3. Neumann AU, Lam NP, Dahari H, et al. Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferonalpha therapy.Science 1998; 282: 103–7.

    Article  PubMed  CAS  Google Scholar 

  4. Lam NP, Neumann AU, Gretch DR, Wiley TE, Perelson AS, Layden TJ. Dose-dependent acute clearance of hepatitis C genotype 1 virus with interferon alfa.Hepatology 1997; 26: 226–31.

    Article  PubMed  CAS  Google Scholar 

  5. Zeuzem S, Lee JH, Franke A, et al. Quantification of the initial decline of serum hepatitis C virus RNA and response to interferon alfa.Hepatology 1998; 27: 1149–56.

    Article  PubMed  CAS  Google Scholar 

  6. Zeuzem S, Herrmann E, Lee JH, et al. Viral kinetics in patients with chronic hepatitis C treated with standard or peginterferon alpha-2a.Gastroenterology 2001; 120: 1438–47.

    Article  PubMed  CAS  Google Scholar 

  7. Neumann AU, Zeuzem S, Brunda MJ, Hoffman JH. Rapid viral response to treatment with pegylated (40 kDa) interferon alfa-2a (Pegasys) is strongly predictive of a sustained virologic response in patients with chronic hepatitis C [abstract].Hepatology 2000; 32: 318A.

    Google Scholar 

  8. Shiffman ML. Use of high-dose interferon in the treatment of chronic hepatitis C.Semin Liver Dis 1999; 19 (Suppl 1): 25–33.

    PubMed  CAS  Google Scholar 

  9. Zeuzem S. Induction therapy in chronic hepatitis C: deja-vu with pegylated interferons?.J Hepatol 2004; 41: 488–90.

    Article  PubMed  Google Scholar 

  10. Pawlotsky JM. Therapy of hepatitis C: from empiricism to eradication.Hepatology 2006; 43 (Suppl 1): S207-S220.

    Article  PubMed  CAS  Google Scholar 

  11. Mangia A, Santoro R, Minerva N, et al. Peginterferon alfa-2b and ribavirin for 12 vs 24 weeks in HCV genotype 2 or 3.N Engl J Med 2005; 352: 2609–17.

    Article  PubMed  CAS  Google Scholar 

  12. AISF (Associazione Italiana per lo Studio del Fegato). Trattamento della epatite da HCV. A cura della Commissione Terapia Antivirale, 2004. http://www.webaisf.org/commconl.htm

  13. Poynard T, McHutchison J, Manns M, et al. Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C.Gastroenterology 2002; 122: 1303–13.

    Article  PubMed  CAS  Google Scholar 

  14. Schalm SW. Treatment of patients with cirrhosis. National Institutes of Health Consensus Conference. http://www.hepnet.com

  15. Camma C, Licata A, Cabibbo G, Latteri F, Craxi A. Treatment of hepatitis C: critical appraisal of the evidence.Expert Opin Pharmacother 2005; 6: 399–408.

    Article  PubMed  CAS  Google Scholar 

  16. Falck-Ytter Y, Kale H, Mullen KD, Sarbah SA, Sorescu L, McCullough AJ. Surprisingly small effect of antiviral treatment in patients with hepatitis C.Ann Intern Med 2002; 136: 288–92.

    PubMed  CAS  Google Scholar 

  17. Koike K. Hepatitis C virus infection can present with metabolic disease by inducing insulin resistance.Intervirology 2006; 49: 51–7.

    Article  PubMed  CAS  Google Scholar 

  18. Harrison SA, Brunt EM, Qazi RA, et al. Effect of significant histologic steatosis or steatohepatitis on response to antiviral therapy in patients with chronic hepatitis C.Clin Gastroenterol Hepatol 2005; 3: 604–9.

    Article  PubMed  Google Scholar 

  19. Lonardo A, Loria P, Adinolfi LE, Carulli N, Ruggiero G. Hepatitis C and steatosis: a reappraisal.J Viral Hepat 2006; 13: 73–80.

    Article  PubMed  CAS  Google Scholar 

  20. Walsh MJ, Jonsson JR, Richardson MM, et al. Non-response to antiviral therapy is associated with obesity and increased hepatic expression of suppressor of cytokine signalling 3 (SOCS-3) in patients with chronic hepatitis C, viral genotype 1.Gut 2006; 55: 529–35.

    Article  PubMed  CAS  Google Scholar 

  21. Yaginuma R, Ikejima K, Okumura K, et al. Hepatic steatosis is a predictor of poor response to interferon alpha-2b and ribavirin combination therapy in Japanese patients with chronic hepatitis C.Hepatol Res 2006, in press.

  22. Shiina M, Rehermann B. Hepatitis C vacciness: inducing and challenging memory T cells.Hepatology 2006; 43: 1395–8.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Divisione di Medicina Interna, Dipartimento di Medicina, Endocrinologia, Metabolismo e Geriatria, Università degli Studi di Modena e Reggio Emilia, Nuovo Ospedale S. Agostino-Estense, Via Giardini 1355, 41100, Modena, Italy

    Nicola Carulli

Authors
  1. Nicola Carulli
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Nicola Carulli.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Carulli, N. The faster the better?. Int Emergency Med 1, 91–93 (2006). https://doi.org/10.1007/BF02936531

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF02936531

Keywords

Search

Navigation